Overview: HBV DNA Qualitative PCR TestIntroduction: The HBV DNA Qualitative PCR Test detects hepatitis B viral DNA to confirm infection, causing jaundice or liver pain. Aligned with 2023 AASLD guidelines, it uses PCR for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in virology for patients with suspected hepatitis B infection.
Other Names: HBV DNA Qual Assay, Hepatitis B PCR Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HBV DNA testing began in the 1990s with PCR development. Qualitative PCR assays improved in the 2000s, enhancing infection detection.
Purpose: Confirms hepatitis B infection, guides antiviral therapy, and detects HBV DNA in patients with jaundice or liver pain.
Test Parameters: 1. HBV DNA (Qualitative)
Pretest Condition: No fasting required. Collect whole blood, plasma, serum, or saliva at any time. Report symptoms like jaundice, liver pain, or fatigue, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-4 mL plasma (EDTA), 2-5 mL serum (SST), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document jaundice, liver pain, fatigue, or history of hepatitis B. Include current medications, vaccination status, or risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses PCR to detect HBV DNA presence. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low viral load can affect results. Antiviral therapy may suppress DNA detection.
Clinical Significance: Positive HBV DNA confirms active hepatitis B, prompting antiviral therapy. Negative results may require repeat testing in early infection.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: HBsAg, anti-HBc, or liver function tests to confirm hepatitis B and assess liver damage.
Test Limitations: False negatives may occur in early infection or low viral load. Clinical correlation is needed.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
